Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Research Report 2021

1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Overview

• 1.1 Product Overview and Scope of T-Cell & NK-Cell Engaging Bispecific Antibodies
• 1.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Type
  • 1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Recombinant Monoclonal Antibodies
  • 1.2.3 In-House Bispecific Antibodies
• 1.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Application
  • 1.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Comparison by Application: (2021-2027)
  • 1.3.2 Immunotherapy of Cancer
  • 1.3.3 Clinical Experiment
• 1.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Estimates and Forecasts
  • 1.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 2016-2027
  • 1.4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2016-2027
  • 1.4.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region: 2016 Versus 2021 Versus 2027

2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Competition by Manufacturers

• 2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Sites, Area Served, Product Type
• 2.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Competitive Situation and Trends
  • 2.5.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest T-Cell & NK-Cell Engaging Bispecific Antibodies Players Market Share by Revenue
  • 2.5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario by Region

• 3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
  • 3.3.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
  • 3.3.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
  • 3.4.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
  • 3.4.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Region
  • 3.5.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region
  • 3.5.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
  • 3.6.1 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
  • 3.6.2 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
  • 3.7.2 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Analysis by Type

• 4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2016-2021)
• 4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2016-2021)
• 4.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Type (2016-2021)

5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Analysis by Application

• 5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2016-2021)
• 5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2016-2021)
• 5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 AbbVie
  • 6.1.1 AbbVie Corporation Information
  • 6.1.2 AbbVie Description and Business Overview
  • 6.1.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 AbbVie Product Portfolio
  • 6.1.5 AbbVie Recent Developments/Updates
• 6.2 Astellas Pharma
  • 6.2.1 Astellas Pharma Corporation Information
  • 6.2.2 Astellas Pharma Description and Business Overview
  • 6.2.3 Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Astellas Pharma Product Portfolio
  • 6.2.5 Astellas Pharma Recent Developments/Updates
• 6.3 GEMoaB Monoclonals
  • 6.3.1 GEMoaB Monoclonals Corporation Information
  • 6.3.2 GEMoaB Monoclonals Description and Business Overview
  • 6.3.3 GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 GEMoaB Monoclonals Product Portfolio
  • 6.3.5 GEMoaB Monoclonals Recent Developments/Updates
• 6.4 Immunocore
  • 6.4.1 Immunocore Corporation Information
  • 6.4.2 Immunocore Description and Business Overview
  • 6.4.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Immunocore Product Portfolio
  • 6.4.5 Immunocore Recent Developments/Updates
• 6.5 Molecular Partners
  • 6.5.1 Molecular Partners Corporation Information
  • 6.5.2 Molecular Partners Description and Business Overview
  • 6.5.3 Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Molecular Partners Product Portfolio
  • 6.5.5 Molecular Partners Recent Developments/Updates
• 6.6 Roche
  • 6.6.1 Roche Corporation Information
  • 6.6.2 Roche Description and Business Overview
  • 6.6.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Roche Product Portfolio
  • 6.6.5 Roche Recent Developments/Updates
• 6.7 AstraZeneca
  • 6.6.1 AstraZeneca Corporation Information
  • 6.6.2 AstraZeneca Description and Business Overview
  • 6.6.3 AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 AstraZeneca Product Portfolio
  • 6.7.5 AstraZeneca Recent Developments/Updates
• 6.8 Merck & Co.
  • 6.8.1 Merck & Co. Corporation Information
  • 6.8.2 Merck & Co. Description and Business Overview
  • 6.8.3 Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Merck & Co. Product Portfolio
  • 6.8.5 Merck & Co. Recent Developments/Updates
• 6.9 Pfizer
  • 6.9.1 Pfizer Corporation Information
  • 6.9.2 Pfizer Description and Business Overview
  • 6.9.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Pfizer Product Portfolio
  • 6.9.5 Pfizer Recent Developments/Updates
• 6.10 Eli Lilly
  • 6.10.1 Eli Lilly Corporation Information
  • 6.10.2 Eli Lilly Description and Business Overview
  • 6.10.3 Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Eli Lilly Product Portfolio
  • 6.10.5 Eli Lilly Recent Developments/Updates
• 6.11 IGM Biosciences
  • 6.11.1 IGM Biosciences Corporation Information
  • 6.11.2 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.11.3 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 IGM Biosciences Product Portfolio
  • 6.11.5 IGM Biosciences Recent Developments/Updates
• 6.12 Novartis
  • 6.12.1 Novartis Corporation Information
  • 6.12.2 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.12.3 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Novartis Product Portfolio
  • 6.12.5 Novartis Recent Developments/Updates
• 6.13 BenHealth Biopharmaceuticals
  • 6.13.1 BenHealth Biopharmaceuticals Corporation Information
  • 6.13.2 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.13.3 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.13.4 BenHealth Biopharmaceuticals Product Portfolio
  • 6.13.5 BenHealth Biopharmaceuticals Recent Developments/Updates
• 6.14 CytomX Therapeutics
  • 6.14.1 CytomX Therapeutics Corporation Information
  • 6.14.2 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.14.3 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.14.4 CytomX Therapeutics Product Portfolio
  • 6.14.5 CytomX Therapeutics Recent Developments/Updates
• 6.15 Janssen
  • 6.15.1 Janssen Corporation Information
  • 6.15.2 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.15.3 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.15.4 Janssen Product Portfolio
  • 6.15.5 Janssen Recent Developments/Updates
• 6.16 Lava Therapeutics
  • 6.16.1 Lava Therapeutics Corporation Information
  • 6.16.2 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.16.3 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.16.4 Lava Therapeutics Product Portfolio
  • 6.16.5 Lava Therapeutics Recent Developments/Updates
• 6.17 MacroGenics
  • 6.17.1 MacroGenics Corporation Information
  • 6.17.2 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.17.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.17.4 MacroGenics Product Portfolio
  • 6.17.5 MacroGenics Recent Developments/Updates
• 6.18 Maverick Therapeutics
  • 6.18.1 Maverick Therapeutics Corporation Information
  • 6.18.2 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.18.3 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.18.4 Maverick Therapeutics Product Portfolio
  • 6.18.5 Maverick Therapeutics Recent Developments/Updates
• 6.19 VBL Therapeutics
  • 6.19.1 VBL Therapeutics Corporation Information
  • 6.19.2 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.19.3 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.19.4 VBL Therapeutics Product Portfolio
  • 6.19.5 VBL Therapeutics Recent Developments/Updates
• 6.20 Amgen
  • 6.20.1 Amgen Corporation Information
  • 6.20.2 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
  • 6.20.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
  • 6.20.4 Amgen Product Portfolio
  • 6.20.5 Amgen Recent Developments/Updates

7 T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Cost Analysis

• 7.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies
• 7.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors List
• 8.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Customers

9 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Dynamics

• 9.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends
• 9.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Drivers
• 9.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
• 9.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints

10 Global Market Forecast

• 10.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Type (2022-2027)
• 10.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2022-2027)
• 10.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List